pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
6d
5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry
stat
6d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
7d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
7d
STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
stat
7d
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
stat
7d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
7d
BMS R&D head to depart amid restructure
biospace
7d
Experts update prostate cancer screening guidelines for men
stat
7d
Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1
endpoints
7d
Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
fiercebiotech
8d
All of Us study finds thousands of new genetic variants affecting drug responses
stat
8d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
8d
STAT+: BMI alternative would flip obesity diagnosis for millions, study finds
stat
8d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
9d
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
stat
9d
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
stat
9d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
9d
London biotech Oyster harvests $60M for tau-targeting brain drugs
biopharma dive
10d
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
stat
10d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
10d
Argenx to buy peptide platform in potentially billion-dollar deal
biopharma dive
10d
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
endpoints
10d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
10d
#AHA26: Lilly gets another sleep apnea win, this time with obesity pill
endpoints
10d
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
stat
13d
Democrats’ midterm victory, and a questionable fertility procedure
stat
13d
New evidence for ancient cannabis use
stat
13d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
← prev
page 2 of 25
next →